Citations

Showing 10 of 108119 citations.

Per‐voxel constraints to minimize hot spots in linear energy transfer‐guided robust optimization for base of skull head and neck cancer patients in IMPT
Feng, Hongying , Shan, Jie , Wong, William W. , Foote, Robert L. , Patrick, Christopher L., Tinnon, Kathryn B., Fatyga, M., Patel, Samir H. , Anderson, Justin D. , Schild, Steven E. , Fatyga, Mirek, Bues, Martin , Anderson, Justin D., Liu, Wei

Mayo Clinic

Medical Physics | November 29, 2021 | Volume: 49 | Issue: 1 | Pages: 632-647

10.1002/mp.15384 | PMID 34843119 Get It

AbstractPurposeDue to the employment of quadratic programming using soft constraints to implement dose volume constraints and the “trial‐and‐error” procedure needed to achieve a clinically acceptable plan, conventional dose volume constraints (upper limit) are not adequately effective in controlling small and isolated hot spots in the dose/linear energy transfer (LET) distribution. Such hot spots can lead to adverse events. In order to mitigate the risk of brain necrosis, one of the most clinically significant adverse events in patients receiving intensity‐modulated proton therapy (IMPT) for base of skull (BOS) cancer, we propose per‐voxel constraints to minimize hot spots in LET‐guided robust optimization.Methods and materialsTen BOS cancer patients treated with IMPT were carefully selected by meeting one of the following conditions: (1) diagnosis of brain necrosis during follow‐up; and (2) considered high risk for brain necrosis by not meeting dose constraints to the brain. An optimizing structure (BrainOPT) and an evaluating structure (BrainROI) that both contained the aforementioned hot dose regions in the brain were generated for optimization and evaluation, respectively. Two plans were generated for every patient: one using conventional dose‐only robust optimization, the other using LET‐guided robust optimization. The impact of LET was integrated into the optimization via a term of extra biological dose (xBD). A novel optimization tool of per‐voxel constraints to control small and isolated hot spots in either the dose, LET, or combined (dose/LET) distribution was developed and used to minimize dose/LET hot spots of the selected structures. Indices from dose‐volume histogram (DVH) and xBD dose‐volume histogram (xBDVH) were used in the plan evaluation. A newly developed tool of the dose‐LET‐volume histogram (DLVH) was also adopted to illustrate the underlying mechanism. Wilcoxon signed‐rank test was used for statistical comparison of the DVH and xBDVH indices between the conventional dose‐only and the LET‐guided robustly optimized plans.ResultsPer‐voxel constraints effectively and efficiently minimized dose hot spots in both dose‐only and LET‐guided robust optimization and LET hot spots in LET‐guided robust optimization. Compared to the conventional dose‐only robust optimization, the LET‐guided robust optimization could generate plans with statistically lower xBD hot spots in BrainROI (VxBD,50 Gy[RBE], p = 0.009; VxBD,60 Gy[RBE], p = 0.025; xBD1cc, p = 0.017; xBD2cc, p = 0.022) with comparable dose coverage, dose hot spots in the target, and dose hot spots in BrainROI. DLVH analysis indicated that LET‐guided robust optimization could either reduce LET at the same dose level or redistribute high LET from high dose regions to low dose regions.ConclusionPer‐voxel constraint is a powerful tool to minimize dose/LET hot spots in IMPT. The LET‐guided robustly optimized plans outperformed the conventional dose‐only robustly optimized plans in terms of xBD hot spots control.
Faculty Opinions recommendation of Inhibition of phosphodiesterase type 9 reduces obesity and cardiometabolic syndrome in mice.
Borlaug, Barry A.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 29, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.740948663.793589991 Get It

Faculty Opinions recommendation of Energetic Basis for Exercise-Induced Pulmonary Congestion in Heart Failure With Preserved Ejection Fraction.
Borlaug, Barry A.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 29, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.741174652.793589990 Get It

A feasibility study of virtual group therapy to improve quality of life of cancer caregivers
Lapid, Maria I. , Atherton, Pamela J., Kung, Simon , Clark, Matthew M. , Sloan, Jeff A. , Whitford, Kevin J. , Gentry, Melanie T. , Miller, Janis J., Rummans, Teresa A. , Hubbard, Joleen M. , Gentry, Melanie T , Lapid, Maria I. , Atherton, Pamela J.

Mayo Clinic

Journal of Psychosocial Oncology | November 29, 2021 | Volume: 40 | Issue: 6 | Pages: 854-867

10.1080/07347332.2021.2000550 | PMID 34842060 Get It

Marfan Syndrome Presenting as Spontaneous Coronary Artery Dissection and Arteriopathy
Blech, Benzion, Dhamija, Radhika, Ingall, Timothy, Dhamija, Radhika , Dhamija, Radhika , Blech, Benzion, Ingall, Timothy

Mayo Clinic

The Neurologist | November 29, 2021 | Volume: 27 | Issue: 1 | Pages: 34-36

10.1097/nrl.0000000000000358 | PMID 34842564 Get It

Introduction: Spontaneous coronary artery dissection (SCAD) is a term used to define a spontaneous separation of the coronary artery wall not related to underlying risk factors, such as trauma or underlying atherosclerotic disease. While SCAD has a range of different etiologies, with fibromuscular dysplasia being the most common, most cases of SCAD have no concomitant arteriopathy. Case Report: Here we describe a case of a patient who presented to our institution with SCAD and evidence of an asymptomatic arteriopathy involving extracranial segments of the carotid and vertebral arteries, later found to have a pathogenic variant in the FBN1 gene and ultimately diagnosed with Marfan syndrome. This has only been rarely described in the literature as an etiology for SCAD. Conclusion: Although rare, it is important to consider underlying connective tissue disorders in patients presenting with spontaneous coronary artery dissection and arteriopathy without underlying cardiovascular risk factors.
Neuromodulation in the Treatment of Painful Diabetic Neuropathy: A Review of Evidence for Spinal Cord Stimulation
Strand, Natalie , Burkey, Adam R., Strand, Natalie H

Mayo Clinic

Journal of Diabetes Science and Technology | November 29, 2021 | Volume: 16 | Issue: 2 | Pages: 332-340

10.1177/19322968211060075 | PMID 34842478 Get It

Background: Neuropathies, the most common complication of diabetes, manifest in various forms, including entrapments, mononeuropathies or, most frequently, a distal symmetric polyneuropathy. Painful diabetic neuropathy (PDN) in the classic “stocking” distribution is a disease of increasing prevalence worldwide and a condition for which standard medical treatment only provides modest relief. Neuromodulation offers a potential alternative to pharmacotherapies given its demonstrated efficacy in other refractory chronic neuropathic pain syndromes. High-quality evidence from randomized controlled trials (RCTs) is available in these other settings for two approaches to spinal cord stimulation (SCS): (1) conventional low-frequency SCS (LF-SCS), which modulates axonal activity in the dorsal column and is paresthesia-dependent, and (2) high-frequency SCS delivered at 10 kilohertz (10 kHz SCS), which targets neurons in the superficial dorsal horn and is paresthesia-independent. Method: This review examines the evidence for SCS from published RCTs as well as prospective studies exploring the safety and effectiveness of treating PDN with neuromodulation. Results: Two RCTs enrolling 60 and 36 participants with PDN showed treatment with LF-SCS reduced daytime pain by 45% to 55% for up to two years. An RCT testing 10 kHz SCS versus conventional medical management (CMM) in 216 participants with PDN revealed 76% mean pain relief after six months of stimulation. None of the studies revealed unexpected safety issues in the use of neuromodulation in this patient population. Conclusion: These well-designed RCTs address the unmet need for improved PDN therapies and provide data on the safety, effectiveness, and durability of SCS therapy.
Preoperative Intra-articular Steroid Injections as Predictors of Hip Arthroscopy: 2-Year Outcomes
Mujahed, Tala , Makovicka, Justin L. , Wilcox, Justin G. , Economopoulos, Kostas J. , Hassebrock, Jeffrey D. , Pollock, Jordan Riley , Patel, Karan A.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | November 29, 2021 | Volume: 9 | Issue: 11 | Pages: No page available

10.1177/23259671211053817 | PMID 34881337 Get It

Background: In patients with femoroacetabular impingement, preoperative diagnostic injections are commonly used to establish a diagnosis of intra-articular pathology. In some cases, intra-articular steroid injections are also used for therapeutic purposes. Purpose/Hypothesis: The purpose of this study was to determine if a positive response to intra-articular steroid injection was predictive of superior outcomes after hip arthroscopy to determine if the response to intra-articular steroid injection was predictive of outcomes after hip arthroscopy. It was hypothesized that a positive response to a preoperative hip injection would be predictive of improved short- to midterm outcomes after hip arthroscopy. Study Design: Cohort study; Level of evidence, 3. Methods: This was a retrospective study of 208 patients who elected to have ultrasound-guided intra-articular steroid injection before they underwent hip arthroscopy between January 2016 and December 2016. Patients were divided into 2 groups: those who showed improvement in pain after the injection (steroid responder group) and those who showed no response (nonresponder group). The authors compared the preoperative and 2-year postoperative patient-reported outcomes (modified Harris Hip Score [mHHS] and Hip Outcome Score–Activities of Daily Living [HOS-ADL]) and radiographic findings between groups. Clinical endpoints, including rates of revision and conversion to total hip arthroplasty, were also reviewed. Results: There were 88 patients in the nonresponder group and 120 patients in the responder group, with no significant between-group differences in preoperative descriptive variables. The responder group had significantly higher 2-year mHHS and HOS-ADL, pre- to postoperative change in mHHS and HOS-ADL, percentage of patients achieving the patient acceptable symptomatic state (PASS) on the mHHS, and percentage of patients reaching the minimum clinically important difference and the PASS on the HOS-ADL. There was no difference in Tönnis grade, acetabular labrum articular disruption grade, revision rate, or conversion to total hip arthroplasty between the 2 groups. Conclusion: The response to preoperative intra-articular injection did aid in predicting 2-year patient-reported outcomes of hip arthroscopy for femoroacetabular impingement. Overall, the result of a preoperative intra-articular injection can be a helpful clinical tool for surgical decision-making and counseling patients on expected outcomes after hip arthroscopy.
Utility of hyperthermic intraperitoneal chemotherapy in cases of incomplete cytoreductive surgery
Mangieri, Christopher W. , Moaven, Omeed , Valenzuela, Cristian D. , Votanopoulos, Konstantinos I., Shen, Perry , Levine, Edward A. , Levine, Edward A , W Mangieri, Christopher , Moaven, Omeed , Erali, Richard A.

Mayo Clinic

Journal of Surgical Oncology | November 29, 2021 | Volume: 125 | Issue: 4 | Pages: 703-711

10.1002/jso.26759 | PMID 34841542 Get It

AbstractIntroductionHyperthermic intraperitoneal chemotherapy (HIPEC) during cytoreductive surgery (CRS) is typically reserved for a complete or optimal cytoreduction. There is the potential for therapeutic effect of HIPEC with an incomplete cytoreduction, particularly for near optimal cytoreductions.MethodsRetrospective review of incomplete cytoreductions (R2b, R2c) for appendiceal and colorectal primaries. Primary endpoints were overall survival (OS) and progression‐free survival (PFS). Subgroup analysis for primary etiology and specific cytoreductive score.ResultsA total of 121 cases of incomplete CRS, 74 CRS alone, and 47 CRS‐HIPEC. For the entire study group there was a survival benefit with HIPEC. OS and PFS were 2.3 versus 1.4 (p = 0.001) and 1.6 versus 0.7 (p < 0.0001) respectively for cases with and without HIPEC. Subgroup analysis of appendiceal neoplasms, 43 CRS‐HIPEC and 50 CRS alone, found HIPEC benefit persisted; OS and PFS were 2.4 versus 1.5 (p = 0.016) and 1.7 versus 0.8 (p < 0.0001), respectively for cases with and without HIPEC. Benefit most pronounced in low‐grade cases with doubling of the OS and PFS (p = 0.004). With colorectal primary cases, 10 CRS‐HIPEC and 18 CRS alone, no difference in OS and PFS. When stratifying out by cytoreduction scores, R2b and R2c, HIPEC only provided a benefit for R2b cases; OS and PFS for R2b cases were 2.28 versus 1.01 (p = 0.011) and 1.67 versus 0.75 (p = 0.001), respectively for cases with and without HIPEC.ConclusionHIPEC has utility for incomplete cytoreductions with appendiceal neoplasms, greatest effect with low‐grade appendiceal neoplasms. HIPEC is only beneficial for near optimal cytoreductions (R2b).
Feasibility of Applying Fourier Transform Electrochemical Impedance Spectroscopy in Fast Cyclic Square Wave Voltammetry for theIn VivoMeasurement of Neurotransmitters
Park, Cheonho , Hwang, Sangmun, Kang, Yumin , Sim, Jeongeun, Cho, Hyun U., Oh, Yoonbae , Shin, Hojin , Bennet, Kevin E. , Lee, Kendall H. , Jang, Dong Pyo , Jang, Dong Pyo , Oh, Yoonbae , Kim, Do Hyoung, Blaha, Charles D.

Mayo Clinic

Analytical Chemistry | November 29, 2021 | Volume: 93 | Issue: 48 | Pages: 15861-15869

10.1021/acs.analchem.1c02308 | PMID 34839667 Get It

Topical Cannabinoids for Treating Chemotherapy-Induced Neuropathy: A Case Series
D’Andre, Stacy D. , McAllister, Sean D. , Nagi, Jasdeepa, Ruiz-Macias, Eduardo, Loprinzi, Charles L. , D'Andre, Stacy , Giridhar, Karthik V.

Mayo Clinic

Integrative Cancer Therapies | November 29, 2021 | Volume: 20 | Issue: No issue available | Pages: No page available

10.1177/15347354211061739 | PMID 34841942 Get It

Background Chemotherapy-induced peripheral neuropathy is a common and often severe side effect from many chemotherapeutic agents, with limited treatment options. There is no literature on the use of topical cannabinoids for chemotherapy-induced neuropathy. Case Presentations The current manuscript presents a case series of patients presenting in oncology clinics at Sutter Health, CA and Mayo Clinic, Rochester, MN from April 2019 to December 2020 with chemotherapy-induced peripheral neuropathy who used topical creams containing the cannabinoids delta-nine-tetrahydrocannabinol (THC) and/or cannabidiol (CBD). Conclusions This case series suggests that topical cannabinoids may be helpful for patients with chemotherapy-induced peripheral neuropathy. This paper also discusses the potential mechanisms of action by which topical cannabinoids might alleviate established CIPN symptoms. A randomized placebo-controlled trial using a standardized product is planned to study the actual efficacy of such treatment.